Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors

被引:123
|
作者
Sluis-Cremer, Nicolas [1 ]
Tachedjian, Gilda [2 ,3 ,4 ]
机构
[1] Univ Pittsburgh, Sch Med, Div Infect Dis, Pittsburgh, PA 15261 USA
[2] Macfarlane Burnet Inst Med Res & Publ Hlth, Mol Interact Grp, Melbourne, Vic 3004, Australia
[3] Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia
[4] Monash Univ, Dept Med, Prahran, Vic 3181, Australia
关键词
HIV; reverse transcriptase; non-nucleoside; Gag-Pol; viral entry;
D O I
10.1016/j.virusres.2008.01.002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) are a therapeutic class of compounds that are routinely used, in combination with other antiretroviral drugs, to treat HIV-1 infection. NNRTIs primarily block HIV-1 replication by preventing RT from completing reverse transcription of the viral single-stranded RNA genome into DNA. However, some NNRTIs, such as efavirenz, have been shown to inhibit the late stages of HIV-1 replication by interfering with HIV-1 Gag-Pol polyprotein processing, while others, such as the pyrimidinediones, have been shown to inhibit both HIV-1 RT-mediated reverse transcription and HIV-1/HIV-2 viral entry. Accordingly, in this review we describe the multiple mechanisms by which NNRTIs inhibit HIV-1 reverse transcription (and in some cases HIV-2 reverse transcription) and other key steps involved in HIV-1/HIV-2 replication. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:147 / 156
页数:10
相关论文
共 50 条
  • [21] Clinical experience with non-nucleoside reverse transcriptase inhibitors
    Miller, V
    Staszewski, S
    Boucher, CAB
    Phair, JP
    AIDS, 1997, 11 : S157 - S164
  • [22] Non-nucleoside reverse transcriptase inhibitors for the treatment of AIDS
    Morris, J
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 56 - BIOT
  • [23] Clinical uses of non-nucleoside reverse transcriptase inhibitors
    Harris, M
    Montaner, JSG
    REVIEWS IN MEDICAL VIROLOGY, 2000, 10 (04) : 217 - 229
  • [24] Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors
    Smith, PF
    DiCenzo, R
    Morse, GD
    CLINICAL PHARMACOKINETICS, 2001, 40 (12) : 893 - 905
  • [25] Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors
    Jayaweera, Dushyantha T.
    Espinoza, Luis
    Castro, Jose
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (17) : 3083 - 3094
  • [26] Halolactones are potent HIV-1 non-nucleoside reverse transcriptase inhibitors
    Han, Xin
    Wu, Haoming
    Dong, Chune
    Tien, Po
    Xie, Wei
    Wu, Shuwen
    Zhou, Hai-Bing
    RSC ADVANCES, 2015, 5 (13): : 10005 - 10013
  • [27] Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom
    Pedersen, OS
    Pedersen, EB
    ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1999, 10 (06): : 285 - 314
  • [28] Toxicity of non-nucleoside analogue reverse transcriptase inhibitors
    Kontorinis, N
    Dieterich, DT
    SEMINARS IN LIVER DISEASE, 2003, 23 (02) : 173 - 181
  • [29] Structural aspects of non-nucleoside HIV-1 reverse transcriptase inhibition
    Beyer, Anton
    Lawtrakul, Luckhana
    Pungpo, Pornpan
    Wolschann, Peter
    CURRENT COMPUTER-AIDED DRUG DESIGN, 2007, 3 (02) : 87 - 100
  • [30] Should non-nucleoside reverse transcriptase inhibitors be combined?
    Kappelhoff B.S.
    Huitema A.D.R.
    Beijnen J.H.
    Drugs in R & D, 2005, 6 (2) : 61 - 69